Description: The Development and Production of IVT mRNA therapeutics and vaccines require measuring Critical Quality Attributes (CQAs) like identity, purity, potency, and quantity. Agilent Technologies offers analytical solutions used by top pharmaceutical companies in early-stage drug development through production quality control (QC) and final product release. We’ll explore how Agilent's automated electrophoresis, cell imaging, and LC/MS systems provide trusted results for IVT mRNA workflows, from early-stage development to final product release.
Learning Objectives:
Explore QC throughout the entire IVT mRNA workflow, including data from various nucleic acids and LNP analyses
Discover how Agilent instruments/technologies, such as the Fragment Analyzer and LC/MS systems, can be used for different CQAs
Learn how Agilent is working together with its partners to provide insightful answers for all aspects of the IVT mRNA workflow
.png)
